Meeting
2014 ASCO Annual Meeting
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.
Authors
Michael J. Morris
Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY
Michael J. Morris , Martin Edwin Gleave , Andrew J. Armstrong , Michael Anthony Carducci , Fred Saad , Kristine Peregrino Lacuna , Howard I. Scher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01813370
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5022)
DOI
10.1200/jco.2014.32.15_suppl.5022
Abstract #
5022
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy.
First Author: Michael J. Morris
Poster
2023 ASCO Annual Meeting
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
First Author: Ye Yuan
Poster
2022 ASCO Genitourinary Cancers Symposium
Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.
First Author: Ronald F. Tutrone
Poster
2022 ASCO Genitourinary Cancers Symposium
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.
First Author: Jose De La Cerda